skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

The emerging role of nimotuzumab in the treatment of non-small cell lung cancer

Review

(1710) Views  (720) Full article downloads

Authors: William Boland, Gwyn Bebb

Published Date November 2010 Volume 2010:4 Pages 289 - 298
DOI: http://dx.doi.org/10.2147/BTT.S8617

William Boland1, Gwyn Bebb2,3
1Department of Anatomy and Cell Biology, McGill University, Montreal, Quebec, Canada; 2Tom Baker Cancer Centre, Calgary, Alberta, Canada; 3University of Calgary, Calgary, Alberta, Canada

Abstract: Current non-small cell lung cancer (NSCLC) chemotherapy and radiotherapy regimens, although showing definite survival benefit, still leave patients with a disappointing 15% 5-year overall survival rate. Because of the need to improve traditional outcomes, research has focused on identifying specific tumorigenic pathways that may serve as therapeutic targets. The most successful strategies to date are those aimed at the epidermal growth factor receptor (EGFR), which is found to be upregulated in 40%–80% of NSCLC. Several tyrosine kinase inhibitors and monoclonal antibodies (mAbs) have been developed that inhibit the EGFR receptor and have demonstrated clinical benefit in trials as single agents and in combination regimens. Here we discuss one such agent, the mAb nimotuzumab, the background of its development, its clinical experience in NSCLC thus far, and the rationale for expanding its use to other NSCLC treatment settings.

Keywords: non-small cell lung cancer, chemotherapy, radiotherapy, overall survival, EGFR






Readers of this article also read:

Tipifarnib in the treatment of acute myeloid leukemia
Safety of etanercept in elderly subjects with rheumatoid arthritis
Management of patients with advanced non-small cell lung cancer: role of gefitinib
Advances in diagnostic and treatment options in patients with fibromyalgia syndrome
The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma
Effects of ‘hoja de malvón’ disease on the composition, sensory properties and preference of Malbec wines from Mendoza, Argentina
Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase
Monoclonal antibodies and Fc fragments for treating solid tumors
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University

  • Journal Indexing

    See where all the Dove Press journals are indexed